LTR Pharma Limited (AU:LTP) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
LTR Pharma Limited’s Director, Lee Rodne, has been granted 100,000 unlisted options at an exercise price of $2.52, set to expire in December 2028. This change reflects shareholder approval during the company’s 2024 Annual General Meeting. Such updates may influence investor perceptions and market activity around LTR Pharma’s stock.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.